LGALS9 and neoplasm: In the mouse models of triple-negative breast cancer, 4-1BB, a galectin-9-neutralizing antibody in combination with an agonist antibody to the tumor necrosis factor receptor (TNFR) synergistically inhibited tumor growth and prolonged mouse survival (144).